Research Papers:

Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma

Kwang Hyun Kim, Hyung Ho Lee, Young Eun Yoon, Joon Chae Na, Sook Young Kim, Young In Cho, Sung Joon Hong and Woong Kyu Han _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:662-667. https://doi.org/10.18632/oncotarget.23087

Metrics: PDF 1402 views  |   HTML 2125 views  |   ?  


Kwang Hyun Kim1,2, Hyung Ho Lee3, Young Eun Yoon4, Joon Chae Na5, Sook Young Kim5, Young In Cho6, Sung Joon Hong5,6 and Woong Kyu Han5,6

1Department of Urology, Ewha Womans University College of Medicine, Seoul, Republic of Korea

2Department of Medicine, The Graduate School of Yonsei University, Seoul, Republic of Korea

3Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea

4Department of Urology, Hanyang University College of Medicine, Seoul, Republic of Korea

5Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea

6Brain Korean 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence to:

Woong Kyu Han, email: [email protected]

Keywords: carcinoma; renal cell; area under curve; early diagnosis

Received: August 16, 2017     Accepted: November 17, 2017     Published: December 10, 2017


To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628–0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (>50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23087